

REMARKS

Any fees that may be due in connection with filing this paper or with this application during its entire pendency may be charged to Deposit Account No. 02-1818. If a Petition for Extension of Time is required, this paper is to be considered such Petition, and any fee charged to Deposit Account No. 02-1818.

Supplemental Information Disclosure Statements

Provided here are copies of *Supplemental Information Disclosure Statements* that were mailed February 07, 2008, July 10, 2008 and April 16, 2009. Receipt of these *Supplemental Information Disclosure Statements* was acknowledged by the Office as evidenced by the date stamp on the first page, indicating the dates of February 07, 2008, July 10, 2008 and April 16, 2009. The *Supplemental Information Disclosure Statements* included copies of Office Actions, Examination Reports, and Search Reports that issued in related cases, and a Table with a box for the Examiner to initial that the Examiner considered the Office Actions, Examination Reports, and Search Reports. These *Supplemental Information Disclosure Statements* were mis-coded in the system as Transmittal Letters. Applicant's representative contacted Examiner Lin, who indicated that he would initial the tables evidencing consideration of the Office Actions from the related cases. For the convenience of the Examiner, copies are attached hereto.

Change in Entity Status

A change in Assignee of this application from Nautilus Biotech, S.A. to HANALL PHARMACEUTICAL Co. Ltd. has necessitated a change in entity status. The assignment to HANALL PHARMACEUTICALS was recorded on July 13, 2009, at *Reel 023039, Frame 0017*.

Comments on Examiner's Statement of Reasons for Allowance

The Examiner states that the:

The prior art does not teach a high throughput method of directed evolution where mutations are introduced into a protein one by one along the full length of the protein an individually expressing each protein and then replacing the hit amino acids with all other amino acids and individually expressing and screening these modified hits to identify leads with a predetermined activity or property.

Applicant recognizes that in accord with M.P.E.P. §1302.14, the Examiner's reasons for allowance, as set forth in the *Notice of Allowance*, dated August 13, 2009, need not set forth all of the details as to why the claims are allowed. Applicant does not concede that the Examiner's stated reasons for allowance are the only reasons for which the claims are allowable. In addition, Applicant notes that none of the art of record, singly or in any

Applicant : Manuel Vega *et al.*
Serial No. : 10/022,249
Filed : December 17, 2001


Attorney Docket No. 3800073.00002/ 911
Comments on Reasons for Allowance

combination teaches or suggests a high throughput method of directed evolution in which mutations are introduced into a protein replacing one amino acid per molecule along a particular domain of the protein and expressing each protein separately and then replacing the hit amino acids with all other amino acids and separately expressing and screening these modified hits to identify leads. None of the art of record described high throughput methods in which mutations are introduced one per molecule, hits identified and each hit replaced with all other amino acids and each such protein screened.

* * *

Entry of these remarks into the file history of the above-captioned application respectfully is requested.

Respectfully submitted,



Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 3800073.00002 / 911
Address all correspondence to: 77202
Stephanie Seidman
K&L Gates LLP
3580 Carmel Mountain Road, Suite 200
San Diego, CA 92130-6766
Telephone: (858) 509-7400
Facsimile: (858) 509-7466
email: stephanie.seidman@klgates.com